1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. North America Influenza Vaccines Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. North America Influenza Vaccines Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Increase in flu outbreaks and seasonal epidemics
- 5.1.2 Rising awareness and vaccination campaigns
5.2 Market Opportunities
- 5.2.1 Expansion in vaccination programs
- 5.2.2 Rise in government-funded vaccination initiatives
5.3 Future Trends
- 5.3.1 Development of universal flu vaccines
- 5.3.2 Growth in needle-free vaccine technologies
5.4 Impact of Drivers and Restraints
6. North America Influenza Vaccines Market Regional Analysis
6.1 North America Influenza Vaccines Market Overview
6.2 North America Influenza Vaccines Market Revenue 2020-2028 (US$ Million)
6.3 North America Influenza Vaccines Market Forecast Analysis
7. North America Influenza Vaccines Market Analysis – by Vaccine Type
7.1 Quadrivalent Vaccines
- 7.1.1 Overview
- 7.1.2 Quadrivalent Vaccines: North America Influenza Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Trivalent Vaccines
- 7.2.1 Overview
- 7.2.2 Trivalent Vaccines: North America Influenza Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Influenza Vaccines Market Analysis – by Virus Type
8.1 Influenza Virus Type A
- 8.1.1 Overview
- 8.1.2 Influenza Virus Type A: North America Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Influenza Virus Type B
- 8.2.1 Overview
- 8.2.2 Influenza Virus Type B: North America Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Influenza Vaccines Market Analysis – by Technology
9.1 Egg-based
- 9.1.1 Overview
- 9.1.2 Influenza Virus Type B: North America Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Cell-based
- 9.2.1 Overview
- 9.2.2 Influenza Virus Type B: North America Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
10. North America Influenza Vaccines Market – North America Analysis
10.1 North America
- 10.1.1 North America Influenza Vaccines Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 10.1.1.1 North America Influenza Vaccines Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 US:
North America Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.1.1 US: North America Influenza Vaccines Market Breakdown, by Vaccine Type
- 10.1.1.1.2 US: North America Influenza Vaccines Market Breakdown, by Virus Type
- 10.1.1.1.3 US: North America Influenza Vaccines Market Breakdown, by Technology
- 10.1.1.2 Canada:
North America Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.2.1 Canada: North America Influenza Vaccines Market Breakdown, by Vaccine Type
- 10.1.1.2.2 Canada: North America Influenza Vaccines Market Breakdown, by Virus Type
- 10.1.1.2.3 Canada: North America Influenza Vaccines Market Breakdown, by Technology
- 10.1.1.3 Mexico :
North America Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.3.1 Mexico : North America Influenza Vaccines Market Breakdown, by Vaccine Type
- 10.1.1.3.2 Mexico : North America Influenza Vaccines Market Breakdown, by Virus Type
- 10.1.1.3.3 Mexico : North America Influenza Vaccines Market Breakdown, by Technology
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. North America Influenza Vaccines Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 AstraZeneca
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Emergent BioSolutions Inc.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Mitsubishi Chemical Group Corporation
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Moderna, Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 MYLAN N.V.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Sanofi
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 SEQIRUS
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Serum Institute of India Pvt. Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For North America Influenza Vaccines Market
